Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $4.7B | $1.4B | $836M | $1.1B | 30.5% | 15.6% | 45.1% |
| 2024 | $4.0B | $946M | $576M | $631M | 27.4% | 11.3% | 6.4% |
| 2023 | $3.6B | $917M | $542M | $512M | 26.2% | 24.5% | 58.7% |
| 2022 | $2.9B | $565M | $341M | $305M | 16.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 4,662 |
| Operating Revenue | 4,662 |
| Cost Of Revenue | 1,860.10 |
| Gross Profit | 2,801.90 |
| Operating Expense | 1,890.10 |
| Research And Development | 599.10 |
| Selling General And Administration | 1,291 |
| Total Expenses | 3,750.20 |
| Operating Income | 911.80 |
| Total Operating Income As Reported | 911.80 |
| EBITDA | 1,358.50 |
| Normalized EBITDA | 1,358.50 |
| EBIT | 1,106.70 |
| Interest Income | 112.70 |
| Interest Expense | 18.30 |
| Net Interest Income | 94.40 |
| Other Non Operating Income Expenses | 4.10 |
| Other Income Expense | 82.20 |
| Interest Income Non Operating | 112.70 |
| Interest Expense Non Operating | 18.30 |
| Net Non Operating Interest Income Expense | 94.40 |
| Pretax Income | 1,088.40 |
| Tax Provision | 252.10 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 836.30 |
| Net Income From Continuing And Discontinued Operation | 836.30 |
| Net Income From Continuing Operation Net Minority Interest | 836.30 |
| Net Income | 836.30 |
| Net Income Common Stockholders | 836.30 |
| Net Income Including Noncontrolling Interests | 836.30 |
| Normalized Income | 836.30 |
| Diluted NI Availto Com Stockholders | 847.30 |
| Basic Average Shares | 390.20 |
| Diluted Average Shares | 405.50 |
| Reconciled Depreciation | 251.80 |
| Reconciled Cost Of Revenue | 1,860.10 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Other Special Charges | - |
| Depreciation Amortization Depletion Income Statement | - |
| Depreciation And Amortization In Income Statement | - |
| Earnings From Equity Interest | 78.10 |
| Average Dilution Earnings | 11 |
| Amortization | - |
| Amortization Of Intangibles Income Statement | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| DexCom, Inc.this co. | DXCM | $28.0B | 33.49↑ premium | 10.20 | 30.5% | 20.97 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| IQVIA Holdings Inc. | IQV | $31.2B | 22.93 | 4.80 | 20.9% | 13.04 |
| Centene Corporation | CNC | $31.0B | -4.64 | 1.55 | -33.4% | -6.54 |
| GE HealthCare Technologies Inc. | GEHC | $29.0B | 13.93 |
| - |
| - |
| - |
| - |
| 2.80 |
| 20.1% |
| 9.24 |
| Biogen Inc. | BIIB | $29.0B | 22.43 | 1.59 | 7.1% | 12.51 |
| ResMed Inc. | RMD | $28.2B | 20.12 | 4.72 | 23.5% | 14.47 |
| Mettler-Toledo International Inc. | MTD | $23.9B | 27.44 | - | -3676.8% | 20.87 |
| Insmed Incorporated | INSM | $22.7B | -17.81 | 30.77 | -172.8% | - |
| Peer Median | - | 17.03 | 4.72 | 13.6% | 12.51 | |